Catharina C Moor1, Rémy L M Mostard2, Jan C Grutters3,4, Paul Bresser5, Joachim G J V Aerts1, Niels H Chavannes6, Marlies S Wijsenbeek1. 1. Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, the Netherlands. 2. Department of Respiratory Medicine, Zuyderland Medical, Heerlen, the Netherlands. 3. Department of Pulmonology, Interstitial Lung Diseases Centre of Excellence, St. Antonius Hospital, Nieuwegein, the Netherlands. 4. Division of Heart & Lungs, University Medical Center Utrecht, Utrecht, the Netherlands. 5. Department of Respiratory Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands; and. 6. Department of Public Health and Primary Care, National eHealth Living Lab, Leiden University Medical Center, Leiden, the Netherlands.
Abstract
Rationale: Idiopathic pulmonary fibrosis (IPF) is a deadly disease with increasingly impaired health-related quality of life (HRQOL). eHealth technologies facilitate collection of physiological outcomes and patient-reported outcomes at home, but randomized controlled trials (RCTs) on the effects of eHealth are scarce. Objectives: To investigate whether a home monitoring program improves HRQOL and medication use for patients with IPF. Methods: We performed a multicenter RCT in newly treated patients with IPF. Patients were randomly assigned to standard care or a home monitoring program on top of standard care for 24 weeks. The home monitoring program included home spirometry, reporting of symptoms and side effects, patient-reported outcomes, information, a medication coach, and eConsultations. The primary endpoint was between-group difference in change in King's Brief Interstitial Lung Disease Questionnaire (K-BILD) score at 24 weeks.Measurements and Main Results: A total of 90 patients were randomized (46 assigned to the home monitoring group and 44 to the standard care group). After 24 weeks, no statistically significant difference was found in K-BILD total score, with a 2.70-point increase in the home monitoring group (SD = 9.5) and a 0.03-point increase in the standard care group (SD = 10.4); between-group difference was 2.67 points (95% confidence interval [CI], -1.85 to 7.17; P = 0.24). Between-group difference in psychological domain score was 5.6 points (95% CI, -1.13 to 12.3; P = 0.10), with an increase of 5.12 points in the home monitoring group (SD = 15.8) and a decline of 0.48 points in the standard care group (SD = 13.3). In the home monitoring group, medication was more often adjusted (1 vs. 0.3 adjustments per patient; 95% CI, 0.2 to 1.3; P = 0.027). Patient satisfaction with the home monitoring program was high. Home-based spirometry was highly correlated with hospital-based spirometry over time.Conclusions: The results of this first-ever eHealth RCT in IPF showed that a comprehensive home monitoring program did not improve overall HRQOL measured with K-BILD but tended to improve psychological well-being. Home monitoring was greatly appreciated by patients and allowed for individually tailored medication adjustments.Clinical trial registered with www.clinicaltrials.gov (NCT03420235).
RCT Entities:
Rationale: Idiopathic pulmonary fibrosis (IPF) is a deadly disease with increasingly impaired health-related quality of life (HRQOL). eHealth technologies facilitate collection of physiological outcomes and patient-reported outcomes at home, but randomized controlled trials (RCTs) on the effects of eHealth are scarce. Objectives: To investigate whether a home monitoring program improves HRQOL and medication use for patients with IPF. Methods: We performed a multicenter RCT in newly treated patients with IPF. Patients were randomly assigned to standard care or a home monitoring program on top of standard care for 24 weeks. The home monitoring program included home spirometry, reporting of symptoms and side effects, patient-reported outcomes, information, a medication coach, and eConsultations. The primary endpoint was between-group difference in change in King's Brief Interstitial Lung Disease Questionnaire (K-BILD) score at 24 weeks.Measurements and Main Results: A total of 90 patients were randomized (46 assigned to the home monitoring group and 44 to the standard care group). After 24 weeks, no statistically significant difference was found in K-BILD total score, with a 2.70-point increase in the home monitoring group (SD = 9.5) and a 0.03-point increase in the standard care group (SD = 10.4); between-group difference was 2.67 points (95% confidence interval [CI], -1.85 to 7.17; P = 0.24). Between-group difference in psychological domain score was 5.6 points (95% CI, -1.13 to 12.3; P = 0.10), with an increase of 5.12 points in the home monitoring group (SD = 15.8) and a decline of 0.48 points in the standard care group (SD = 13.3). In the home monitoring group, medication was more often adjusted (1 vs. 0.3 adjustments per patient; 95% CI, 0.2 to 1.3; P = 0.027). Patient satisfaction with the home monitoring program was high. Home-based spirometry was highly correlated with hospital-based spirometry over time.Conclusions: The results of this first-ever eHealth RCT in IPF showed that a comprehensive home monitoring program did not improve overall HRQOL measured with K-BILD but tended to improve psychological well-being. Home monitoring was greatly appreciated by patients and allowed for individually tailored medication adjustments.Clinical trial registered with www.clinicaltrials.gov (NCT03420235).
Entities:
Keywords:
eHealth; home spirometry; idiopathic pulmonary fibrosis; interstitial lung disease; quality of life
Authors: Rossella Di Bidino; Paola Rogliani; Alfredo Sebastiani; Alberto Ricci; Francesco Varone; Giacomo Sgalla; Bruno Iovene; Teresa Bruni; Maria Chiara Flore; Michela D'Ascanio; Francesco Cavalli; Daniela Savi; Loreta Di Michele; Americo Cicchetti; Luca Richeldi Journal: Front Med (Lausanne) Date: 2022-06-09
Authors: Anna J Podolanczuk; Alyson W Wong; Shigeki Saito; Joseph A Lasky; Christopher J Ryerson; Oliver Eickelberg Journal: Am J Respir Crit Care Med Date: 2021-06-01 Impact factor: 21.405
Authors: Imre Noth; Vincent Cottin; Nazia Chaudhuri; Tamera J Corte; Kerri A Johannson; Marlies Wijsenbeek; Stephane Jouneau; Andreas Michael; Manuel Quaresma; Klaus B Rohr; Anne-Marie Russell; Susanne Stowasser; Toby M Maher Journal: Eur Respir J Date: 2021-07-08 Impact factor: 16.671
Authors: Eusebi Chiner-Vives; Rosa Cordovilla-Pérez; David de la Rosa-Carrillo; Marta García-Clemente; José Luis Izquierdo-Alonso; Remedios Otero-Candelera; Luis Pérez-de Llano; Jacobo Sellares-Torres; José Ignacio de Granda-Orive Journal: Arch Bronconeumol Date: 2022-04-15 Impact factor: 6.333
Authors: Orla O'Carroll; Rachel MacCann; Aoife O'Reilly; Eleanor M Dunican; Eoin R Feeney; Silke Ryan; Aoife Cotter; Patrick W Mallon; Michael P Keane; Marcus W Butler; Cormac McCarthy Journal: Eur Respir J Date: 2020-08-13 Impact factor: 16.671
Authors: Catharina C Moor; Sander I van Leuven; Marlies S Wijsenbeek; Madelon C Vonk Journal: Rheumatology (Oxford) Date: 2021-05-14 Impact factor: 7.580